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Resumen
Introducción: Los productos orales sólidos de liberación inmediata que contienen fármacos muy solubles y perme-
ables son candidatos para el proceso de bioexención. Este trabajo tiene como objetivo comparar datos in vitro, in 
silico e in vivo para establecer si las formulaciones de comprimidos orales de prednisona publicadas anteriormente 
son candidatas a la bioexención.
Método: Para lograr este objetivo se realizaron estudios de permeación en células Caco-2. Se aplicó un estudio de 
bioequivalencia previo entre la formulación de prueba y el medicamento de referencia en una evaluación in silico 
utilizando Gastroplus® para evaluar la bioequivalencia de otras dos formulaciones propuestas anteriormente.
Resultados: El coeficiente de permeabilidad aparente para prednisona presentó un valor de 3,69 x 10-5 cm/s en 
180 minutos. El estudio de bioequivalencia muestra que el producto probado y de referencia era equivalente. Las 
simulaciones in silico predijeron con éxito la farmacocinética de las formulaciones probadas y las otras dos, ya que 
fueron validadas con el estudio in vivo. Ambos exhiben los mismos perfiles de concentración plasmática frente a 
tiempo.
Conclusiones: A través de los resultados in silico, es posible inferir que las otras dos formulaciones ensayadas 
pueden ser bioequivalentes respecto al producto de referencia. Este resultado puede ser útil en la solicitud de bio-
exenciones. Para reducir los costos y el uso de seres humanos en los estudios de bioequivalencia, este enfoque 
podría ser una forma esencial de trabajar en la industria farmacéutica.
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Abstract
Introduction: The immediate-release solid oral products containing very soluble and permeable drugs are candi-
dates for the biowaiver process. This work aims to compare in vitro, in silico, and in vivo data to establish if previously 
published prednisone oral tablet formulations are biowaiver candidates.
Method: To achieve this goal, permeation studies were conducted on Caco-2 cells. A previous bioequivalence study 
between the test and the reference drug product was applied on an in silico evaluation using Gastroplus® to assess 
the bioequivalence of two other previously proposed formulations.
Results: The apparent permeability coefficient for prednisone presented a value of 3.69 x 10-5 cm/s in 180 minutes. 
The bioequivalence study shows that the tested and reference product was equivalent. The in silico simulations 
successfully predicted the pharmacokinetics of the tested and the other two formulations since they were validated 
with the in vivo study. Both exhibit the same plasma concentration vs. time profiles.
Conclusions: Through the in silico results, it is possible to infer that the other two formulations tested may be bio-
equivalent concerning the reference product. This result may be helpful in biowaiver requesting. Toward to reduce 
costs and the use of human beings in bioequivalence studies, this approach could be an essential way to work in 
the pharmaceutical industry.
Keywords: prednisone; in silico simulation; bioavailability; biowaiver
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Highlights
In silico pharmacokinetic studies could accelerate the registration process for generic drugs applying 
for biowaiver.
As a biowaiver candidate, the relevance of in silico studies for BCS class I drugs is even more critical, 
given the regulatory scenario.
It may induce regulatory agencies to take a more in-depth view of the dissolution aspects during stabil-
ity studies and how in silico previsions may help develop new projects.
Introduction
As in the USA and Europe, the generic drug registration in Brazil requires bioequivalence (BE) studies. 
Pharmaceutical equivalents drug products are considered bioequivalent and, therefore, interchange-
able when the bioavailability is not statistically different between the products after administration at 
the same dose and under similar experimental conditions in a BE study(1).
Prednisone is a glucocorticoid extensively used in clinical practice for inflammatory diseases. It is con-
sidered borderline class I in the Biopharmaceutical Classification System (BCS), which is highly solu-
ble and permeable. The drug has a plasma protein-binding rate of approximately 90%, bioavailability 
around 80%, and volume of distribution ranges from 0.4 to 1.0 L.kg-1. It has a biological half-life time 
of about 3.6 hours, and maximum serum concentration (Cmax) is reached between one and three hours 
after oral administration. The permeability rate of prednisone in artificial phospholipid membrane is 
0.3 x 10-6 cm/s(2).
In Brazil, prednisone is marketed as immediate-release oral tablets at concentrations of 20 mg and 50 
mg. The reference medicine is named Meticorten®, produced by Merck Sharp & Dome®(3). Numerous 
generic formulations of prednisone registered in the Brazilian market prove the BE with the reference 
product. These tests require resources and time in the formulation development process. Thus, one 
of the main discussions among the academic, industrial, and regulatory arena today revolves around 
biowaivers.
A biowaiver account that relative bioavailability or BE tests are not required for drug registration by the 
regulatory agency when a suitable in vitro assay could replace it(4). The need for the pharmaceutical 
industry to obtain a safe tool that allows an in vitro-in vivo correlation (IVIVC) for a possible biowaiver 
is increasingly higher. The concept and application of this correlation have been focused attention on 
universities, pharmaceutical industries, and regulatory sectors.
The correlation of the in silico simulation with the in vitro and in vivo studies can predict the absorp-
tion, distribution, metabolism, and elimination of several drugs(5). Biowaiver procedure could involve 
an evaluation through computational simulations that delineate a natural or laboratory process. For 
in silico simulation, some software such as SIMCYP™, PK-sim™, CLOEPK™, and GastroPlus® are current-
ly used. However, to obtain a correlation, this software needs some active pharmaceutical ingredient 
(API) input data such as permeability rate, pKa, logP, logD, and solubility(6).
Gastroplus® was used in a previous study to predict oral absorption and BE of two formulations of gly-
buride(7). Also, the in vitro results combined with in silico simulation to justify a biowaiver for etoricox-
ib(8). Even though it is handy in drug bioavailability prediction in the development phase, Brazilian leg-
islation currently does not consider the in silico results to grant exemption or replace bioequivalence 
studies. On the other hand, the biowaiver could be required based on the Biopharmaceutical Classifi-
cation System (BCS)(4,9).
In a previous paper, we presented a pre-formulation study by which a prednisone raw material supplier 
was chosen. Tablet formulations were prepared, and a stability study was conducted to select which 
one should be scaled up. Moreover, we monitored dissolution and dissolution profiles during stability 
study, a not common approach in pharmaceutical literature. Considering the reduction of dissolution 
during stability studies, it could eventually impact the in vivo performance of the product over time(10).
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This work compared in vitro, in silico, and in vivo data to establish if previously published prednisone 
oral tablet formulation is an effective candidate for the biowaiver process. Simultaneously, this paper 
brings a wholly new perspective of biowaiver attempt helping to understand this process better.
Methods
Permeation studies on Caco-2 cells
Cytotoxicity studies
Caco-2 cells (passage 57) were seeded in a 96-well plate, 32,000 cells/well, in a total volume of 200 
microliters/well, using Dulbecco’s Modified Eagle Medium (DMEM, pH 7.40) supplemented with 10% 
(v/v) fetal bovine serum, 1% benzylpenicillin (160 IU/ml) streptomycin sulfate (100 μg/ml) and 1 % of 
non-essential amino acids was used as the culture medium. Cell cultures were maintained at 37 °C, 
95% air atmosphere, 5% CO2, and 95% relative humidity
(11,12) as a culture medium. Subsequently, cell 
substrates were taken to the incubator at 37 ºC and 5% CO2 for 24 hours for cell growth
(13). After 24 
hours, the culture medium was removed from wells, and cells were placed in contact with a 31.5 μg/mL 
solution of prednisone in Hank’s Balanced Salt Solution (HBSS) + 5% ethanol (pH 6.8). HBSS and HBSS 
+ 5% ethanol solutions, both at pH 6.8, were used as control groups.
Samples were stayed connected with Caco-2 cells for 3 hours and then aspirated. Thus, the cells were 
treated with 2.5 mg/mL 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide solution (MTT 
solution in phosphate buffer solution - PBS, pH 7.4), adding 100 μL of HBSS (pH 6.8) and 25 μL of MTT 
solution per well. The plate was incubated for an additional 3 hours at 37 ºC and 5% CO2. MTT solu-
tion was aspirated, and the cells were washed with PBS (pH 7.4) two times. Then 100 μL/well of di-
methylsulfoxide (DMSO) were added for formazan crystals solubilization, generating a violet coloration 
according to the degree of cellular viability. Absorbance readings from the wells were performed on 
Microplate Absorbance Reader (iMARKTM, USA), at 570 nm, using 690 nm as referencing, after vigorous 
shaking for 60 seconds(14,15).
Caco-2 cells monolayer permeability studies
Samples were subjected to permeability tests through Caco-2 cell monolayers during passage 57. Cells 
were seeded onto polycarbonate filters (0.33 cm2, 6.5 mm internal diameter, and 0.4 μm pores) in 24 
well plates at a density of 2.5 x 105 cells/cm2. The cells’ filters were maintained with cell culture medium 
changes for 21 days after seeding and were used for transepithelial electrical resistance and transport 
assays(14-16). The media used for API dilution was HBSS + 5% ethanol (pH = 6.8). This solution was used in 
the apical compartment (donor). HBSS (pH 7.4) mimics the microenvironment under the intestinal epi-
thelium in the basolateral compartment (receptor). Prednisone solution at 31.5 μg/mL was prepared in 
HBSS + 5% ethanol (pH 6.8). Two hundred microliters of this solution were added into the apical com-
partment of the cell monolayer. At fixed times (30, 60, 120, and 180 minutes), each filter and its apical 
compartment were repositioned on a new well containing 600 µL of the fresh basolateral medium. All 
receptor solutions were collected and analysed directly (without dilution) by a UV spectrophotometer 
(λ = 239 nm). The apparent permeability coefficient (Papp) was calculated using Eq. (1).
(1)
Where dQ/dt is the permeability rate (amount of prednisone permeated per minute), A is the diffusion 
area of the cell monolayer, C0 is the initial concentration of prednisone in the apical compartment
(14-16). 
During the experiment, the integrity of the monolayer was evaluated by Transepithelial Electric Resis-
tance (TEER) at fixed intervals (along with collection times) using the Millicell-ERS system (Millipore 
Corp., USA)(14,15). Monolayer integrity was considered when voltages above 350 Ω.cm2 were observed(11).
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Bioequivalence study
The bioequivalence study between the 20 mg prednisone tablets produced by our group (biobatch 
P0020020910) and the reference drug product (Mantercorp® Pharmaceutical) was under the respon-
sibility of the Nucleus of Bioequivalence and Clinical Trials (NuBEC) of the Federal University of São 
Paulo.
An open, randomized, cross-over study was conducted with two treatments, two sequences, and two 
periods, in which volunteers received, in each period, the test or the reference formulation. An amount 
of 26 healthy volunteers, men and women aged between 18 and 50 years, and body mass index ≥ 19 
and ≤ 28.5 kg.m-2 receive one tablet containing 20 mg prednisone fasted orally, uniquely with 200 mL 
of non-gas mineral water. The confinement period was 24 hours. Blood samples for determination of 
plasma concentration of prednisolone were collected before administration and up to 24 hours later 
at pre-established intervals. Plasma concentrations of prednisolone were determined by HPLC-MS(17).
In silico model absorption for prednisone immediate-release tablet
The in silico absorption model was developed using the software GastroPlus® (Version 9.5, Simulation 
Plus Inc., USA). The model was built with the integration between the Advanced Compartmental Ab-
sorption and Transit (ACAT) and pharmacokinetic (PK) model (1, 2, and 3-compartment model). The 
ACAT model describes the gastrointestinal tract like compartments considering drug (unreleased drug, 
dissolved drug, precipitated drug) and physiology (luminal volume, pH, transit time) characteristics. 
Once integrated into the PK information, like distribution volume, clearance, and half-life time, it is 
possible to observe the simulated drug kinetic absorption and exposition in the gastrointestinal tract.
The software has three main input modules: compound, physiology, and pharmacokinetics. The phys-
icochemical (solubility, permeability, pKa) and drug dosage form (tablet, dose, particle size) proper-
ties were inputted at the compound module. These data were taken from the literature or experimen-
tally determined (Table 1). The effective gastrointestinal permeability (Peff) of prednisone (biobatch 
P0020020910) was predicted based on the conversion of the apparent permeability (Papp) with Caco-2 
cells using a built-in correlation of the GastroPlus®. The solubility data was determined in pH 1.2, 5.5, 
and 6.8 aqueous media(8,18,19).
Table 1. Input parameters used for the prednisone IR tablet absorption model.
Parameters Value Reference
Molar mass (g/mol) 358.43 (ANVISA, 2019)
Log P 1.46 (Paixão, Gouveia, & Morais, 2012; Vogt et 
al., 2007)
Dose (mg) 20 BE
Dosage form Tablet IR E
Dose volume (mL) 200 BE
                                 Solubility (mg/mL)
pH 1.2 4.48
(Toehwé et al., 2017)pH 5.5 4.53
pH 6.8 4.55
Papp in Caco-2 (cm/s x 10
-5) 3.69 E
Mean precipitation time (s) 900 s DV
Drug particle radius (g/ml) 1.2 DV
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Parameters Value Reference
Particle radius (µm) 25 DV
Physiology Fasted E
AFS (Model) SA/V 6.1 DV
Body mass (kg) 66.4 BE
Blood/Plasma ratio 1.0 E
Distribution volume (L/kg) 0.69 E
Clearance (L/h) 11,51 E
t1/2 (h) 2.86 E
Simulation Time (h) 24 E
Papp = apparent permeability coefficient; BE = bioequivalence study; E = experimental; DV = GastroPlus®
 default value
In the physiology module, the Opt logD Model SA/V 6.1 estimates the GI tract permeability. The absorp-
tion gradient coefficient C1-C4 was used to calculate the absorption scale factors (ASF) and scale the 
effective permeability to account for absorption rate variations that differ from one compartment to 
another(18,20).
In the pharmacokinetic module, the used data were obtained from the bioequivalence study of the bio-
batch P0020020910, as described above (item 2.3)(10,17). The in vivo plasma concentration versus time 
data was loaded into the PKPlusTM module (integrated module of GastroPlus®) and evaluated by the 
software according to non-compartmental, 1-, 2-, and 3-compartment PK models. The best model pa-
rameters were then imported into the pharmacokinetic module to enable the in silico plasma concen-
tration versus time data(8,18,21). To develop the prednisone absorption model, the “IR tablet mode” was 
selected in the compound module that refers to immediate-release tablets(20,21). Through Eq. (2) it was 
calculated the percent prediction error (%PE) to compare observed and simulated PK parameters(19).
(2)
Results
Permeation studies on Caco-2 cells 
Cytotoxicity and Caco-2 cells monolayer permeability studies
The cytotoxicity assessment was performed to determine whether concentrations of 31.5 μg/mL of API 
and HBSS pH 6.8 + 5% ethanol medium used in the Caco-2 cell permeability test would harm the cells. 
The cell viability was almost 100% for all evaluated media (data not shown), so no cytotoxic effect was 
observed among the tested samples.
After 21 days of culture, the mean transepithelial resistance (TEER) of the Caco-2 cell monolayer was 
711.2 ± 37.05 Ω.cm2. Figure 1 presents the permeation data of prednisone and the mean TEER (Ω) as 
a function of time. At 180 minutes, prednisone permeation reached 65.84% of the initial mass (6.3 μg) 
deposited in the apical compartment.
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Figure 1. Cumulative permeated mass (%) of prednisone across Caco-2 monolayer and TEER values (Ohms) after 
180 minutes.
The apparent permeability coefficient (Papp) for prednisone was calculated from the mean of 5 deter-
minations of the permeability test and presented a value of 3.69 x 10-5 cm/s in the accumulated time of 
180 minutes. It should be observed that this value of Papp was used in the simulation of bioavailability 
by GastroPlus®.
Bioequivalence studies
The mean plasma concentration vs. time curve of prednisolone (active prednisone metabolite) in vol-
unteers using the biobatch P0020020910 and reference drug product (R023) is shown in Figure 2. The 
pharmacokinetic parameters analyzed in the study are described in Table 2.
Table 2. Pharmacokinetic parameters obtained from the mean plasma concentration versus prednisolone time 
curve.
Parameters P0020020910 R023
Average SD Mini Maxi Average SD Mini Maxi
AUC0-t (ng.h/mL) 563.22 120.70 365.38 972.94 598.02 186.89 365.33 1208.02
AUC0-inf (ng.h/mL) 598.50 127.27 380.56 985.52 628.25 187.50 379.12 1222.93
Cmax (median/range) (h) 126.08 27.36 78.36 197.49 131.65 31.52 101.14 247.72
Tmax (median/range) (h) 1.52 0.86 0.75 4.00 1.56 0.78 0.50 3.00
Kel (L/h) 0.25 0.05 0.15 0.33 0.26 0.04 0.14 0.37
t½ (median/amp) (h) 2.82 0.56 2.07 4.49 2.77 0.59 1.86 4.92
SD = standard deviation; Mini = minimum; Maxi = maximum
According to the estimated geometric means ratio between Cmax and the AUC0-t for batches P0020020910, 
and R023 the results obtained for these parameters were 104.24% (99.12%, 109.62%) and 100.60% 
(96.59%, 104.78%), respectively, considering a 90% confidence interval. These results compile with 
the range established by the Guide for tests of relative bioavailability/bioequivalence of medicines(22). 
Therefore, the formulations under study are bioequivalent(17).
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Figure 2. Mean plasma concentration of prednisolone versus time in volunteers following a single dose administra-
tion of prednisone 20 mg tablets of biobatches P0020020910 and R023.
In silico absorption model for prednisone immediate-release tablet
The absorption model was developed for prednisone (biobatch P0020020910) immediate-release tab-
let. The fraction of the amount of drug absorbed was 96.4%. Table 3 presents the prednisone simu-
lated compartmental absorption along to the GI tract. According to the ACAT model, this simulation 
confirmed the high absorption in the proximal region (~93,7%).
The simulated and experimental PK parameters after oral administration of 20 mg prednisone imme-
diate-release tablets (biobatch P0020020910) are presented in Table 4. The predicted outputs and bio-
availability in vivo were almost similar. The predicted errors were lower than 10% for all parameters, 
except for t1/2 in the reference product.
GastroPlus® was used to simulate plasma concentration-time curves for all the products (R023, 
P0020020910, MEST01, and MEST 02). The resulting profiles were then compared to the reference prod-
uct (R023) curve plotted with in vivo experimental values to evaluate the proposed formulations’ in vivo 
performance (Figure 3). According to the predicted plasma concentration-time curves, the biobatch 
P0020020910 show an in vivo performance equivalent to the reference product, as proven by the BE 
studies (Figure 2). Furthermore, the MEST01 and MEST02 formulations would show equally in vivo per-
formance compared to the reference product.
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Table 3. Simulation of the percentage absorbed of prednisone (biobatch P0020020910) along with the compart-












Figure 3. Plasma concentration vs. time curve of the reference product (R023) based on in vivo experimental values 
and of products P0020020910, MEST01, and MEST 02 created using simulated values given by GastroPlus® 
based on in vitro dissolution data(32). The error bars represent the standard deviation for the reference 
plot.
Discussion
Permeation studies on Caco-2 cells
MTT test demonstrated that both drugs and media did not cause cell damage since its viability at the 
end of the experiment was around 100%. This result follows Yamashita and co-workers, which conclud-
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ed that ethanol up to 5% (v/v) does not cause significant permeability and transepithelial resistance 
(TEER). The results also show that HBSS (pH 6.8) and HBSS + 5% ethanol (pH 6.8) media are not altering 
cell viability, as expected(23).
TEER values were compatible with those reported in the literature for mature monolayers(12,15). In Fig-
ure 1, it is possible to observe that the most significant permeate fraction occurred in the interval be-
tween 120 and 180 minutes and that TERR remained above 350 Ω, confirming that monolayer cells 
remained intact throughout the experiment(11).
As stated by the literature, drugs that show absorption between 70% and 100% should have Papp greater 
than 10.0 x 10-6 cm/s(24). A study that evaluated the correlation between biopharmaceutics classification 
system (BCS) and Papp value (cm/s) argued that drugs with Papp greater than 9.75 x 10
-6 cm/s show a 
high, and less than 5.00 x 10-6 cm/s, a low permeability. As previously mentioned, prednisone belongs 
to BCS class I. The Papp obtained in this study for this drug (3.69 x 10
-5 cm/s) corroborates with BCS clas-
sification(25).
According to Vogt and collaborators(2), there are very limited studies reporting the in vitro permeability 
of prednisone since it is a prodrug. However, the FDA Guidance(1) states that the prodrug permeability 
should be measured when the conversion occurs after GI membrane permeation. So, the results about 
Caco-2 cells prednisone permeability could be beneficial in a biowaiver decision.
In silico absorption model for prednisone immediate-release tablet
According to the drug solubility of previous studies and permeability analyzed in this work, prednisone 
is highly soluble and absorbed in the intestinal tract. These characteristics added to an immediate-re-
lease dosage form shown a dissolution profile of ≥85% in 15 minutes(10), suggesting, like other class I 
drugs, that the prednisone can be highly absorbed in the proximal region of the intestine(21,26).
The evaluation of the in vivo plasma concentration vs. time curve by GastroPlus® present that predni-
sone kinetics follow a one-compartmental model. It means that the drug promptly occupies the central 
compartment, and the plasma concentration decrease depends only on the elimination rate constant, 
which follows a first-order process(27,28).
The predicted outputs and BA in vivo (Table 4) suggest that the in silico absorption model based on the 
Table 1 data successfully simulate the in vivo bioavailability of prednisone IR tablets. The lower %PE 
values prove that the model could mimic the in vivo PK parameters. Duque and co-workers successfully 
used the ACAT model in BA simulated of fluconazole, a BCS class I drug, showing that the prediction 
model was also valuable for generic and reference drugs(21). Also, this absorption model was widely 
applied in BCS class II drugs(18,20).
As mentioned, the biowaiver is requested for BCS class I drugs when using immediate-release tablets. 
In this context, a predictive in vitro dissolution could replace the bioequivalence study(29). Once the in 
silico absorption model was developed for prednisone IR tablets, it becomes possible that the bioavail-
ability simulation helps during the optimization of the formulation process. By evaluating the in vivo 
and in silico data, it is possible to infer that an in vivo study is probably unnecessary for these, suggest-
ing the bioequivalence between the MEST 01, MEST 02, R023, and biobatch P002002910.
Table 4. Pharmacokinetic parameters obtained in the in vivo study and simulated by GastroPlus® for biobatch 
P0020020910 and reference product R023.
Parameters Simulated R023 %PE P0020020910 %PE
Cmax (ng/mL) 318.9 298 -7.01% 313 -1.88%
Tmax (h) 1.36 1.17 16.2% 1.50 9.33%
ASC0-t (ng.h/mL) 1730.5 1685.7 2.65% 1718.5 -0.69%
ASC0-inf (ng.h/mL) 1737.1 1769.6 1.83% 1811.6 4.11%
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%PE = percent prediction error
The Brazilian regulatory agency recommendations for the waiver of BE studies according to the BCS 
state that IR solid oral products must have rapid drug dissolution (> 85% in 30 min) in 0.1 HCl, pH 4.5, 
and pH 6.8(4). Previously, the dissolution tests were conducted in purified water, as recommended by 
the Brazilian compendia(10). All the products that meet the requirements of the dissolution rate still 
showed an in silico performance equivalent to the reference product. The very rapid dissolution (85% 
in up to 15 minutes) of the tested prednisone tablets makes the gastric emptying rate the limiting factor 
for in vivo drug absorption, and no more the dissolution rate(30). In some cases, the in vitro dissolution 
method was not discriminative for the in vivo process. Al-Tabakha and co-workers evaluated different 
products containing amoxicillin and potassium clavulanate that was considered bioequivalent but pre-
senting differently in vitro dissolution profiles(31).
On the other hand, to declare that the tested formulations are bioequivalent to the reference product, 
more predictive dissolution studies will be necessary to discriminate the formulation’s performance. 
The use of purified water as dissolution media, although recommended for quality control tests(10), may 
not be adequate for evaluating pharmaceutical equivalence.
Although the results present by this study provide a biowaiver favorable data based on the in silico 
pharmacokinetic study and the BCS, prednisone is at the borderline of the current criteria of BCS class 
I. The biowaiver of prednisone must be carefully evaluated considering its indication, therapeutic in-
dex, pharmacokinetic performance, and the possibility of drug-excipients interaction(2). Due to many 
marked generic products of prednisone and other class I drugs, the use of different formulation excip-
ients could modify their dissolution and oral absorption. Therefore, in vivo bioequivalence studies are 
still needed.
Conclusion
The present study evaluates the in silico bioavailability simulations comparing these data with in vivo 
ones in order to establish if previous published prednisone oral tablet formulation is a valid candi-
date for the biowaiver process. The in silico bioavailability performed for prednisone in the GastroPlus® 
software was successful since the predicted PK parameters were similar to in vivo data. The simulated 
plasma concentration vs. time curve based on the previous dissolution data allows us to infer that the 
proposed formulations MEST01 and MEST02 could be bioequivalent with the reference product. In or-
der to confirm this hypothesis, a predictive dissolution study should be applied.
This work turns available the bioavailability profile obtained in human volunteers and compares refer-
ence and tests drug products, which is not common in the offered publications. More than that, it pres-
ents a viable in silico model to simplify post-approval changes in the regulatory scenario. Prednisone is 
classified as a BCS class I or borderline class I drug and a promising candidate for biowaiver. However, 
a careful evaluation of the excipients used is necessary to claim it. Toward to reduce costs and the use 
of human beings in bioequivalence studies, this approach could be an essential way to work in the 
pharmaceutical industry.
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